

DAFTAR PUSTAKA

1. Ghebreyesus TA. Global Tuberculosis 2023 Report. Vol. 2, World Health Organization. 2024.
2. Tong X, Wang D, Wang H, Liao Y, Song Y, Li Y, et al. Clinical features in pulmonary tuberculosis patients combined with diabetes mellitus in China: An observational study. *Clin Respir J*. 2021 Sep;15(9):1012–8.
3. Lee P-H, Lin H-C, Huang AS-E, Wei S-H, Lai M-S, Lin H-H. Diabetes and risk of tuberculosis relapse: nationwide nested case-control study. *PLoS One*. 2014;9(3):e92623.
4. Banurekha V, Bhatnagar T, Savithri S, Kumar ND, Kangusamy B, Mehendale S. Sputum Conversion and Treatment Success among Tuberculosis Patients with Diabetes Treated under the Tuberculosis Control Programme in an Urban Setting in South India. *Indian J community Med Off Publ Indian Assoc Prev Soc Med*. 2017;42(3):180–2.
5. Shariff NM, Safian N. Diabetes mellitus and its influence on sputum smear positivity at the 2nd month of treatment among pulmonary tuberculosis patients in Kuala Lumpur, Malaysia: A case control study. *Int J Mycobacteriology*. 2015;4(4):323–9.
6. Caetano Mota P, Carvalho A, Valente I, Braga R, Duarte R. Predictors of delayed sputum smear and culture conversion among a Portuguese population with pulmonary tuberculosis. *Rev Port Pneumol*. 2012;18(2):72–9.
7. Babalik A, Kızıldağ Ş, Arda H, Oruc K, Cetintas Afsar G, çalışır H. Factors affecting smear conversion in tuberculosis management. *Med Sci*. 2012 Dec 1;1:1.
8. Huang LK, Wang HH, Lai YC, Chang SC. The impact of glycemic status on radiological manifestations of pulmonary tuberculosis in diabetic patients. *PLoS One*. 2017;12(6):1–13.
9. Zhan S, Juan X, Ren T, Wang Y, Fu L, Deng G, et al. Extensive

Radiological Manifestation in Patients with Diabetes and Pulmonary Tuberculosis: A Cross-Sectional Study. *Ther Clin Risk Manag.* 2022;18:595–602.

10. Fadillah NA, Sulistiana R, Handayani F, Faculty M, Faculty M, Faculty M. Comparison of Chest X-Ray of Pulmonary TB Patients with DM and Non DM at Anutapura Palu Hospital in 2020. *2023;14(01):433–40.*
11. PAHO. Tuberculosis resurges as top infectious disease killer [Internet]. Pan American Health Organization. 2024. p. 1. Available from: [https://www.paho.org/en/news/1-11-2024-tuberculosis-resurges-top-infectious-disease-killer#:~:text=1 November 2024 – The World,global TB monitoring in 1995.](https://www.paho.org/en/news/1-11-2024-tuberculosis-resurges-top-infectious-disease-killer#:~:text=1%20November%202024%20%E2%80%93%20The%20World,global%20TB%20monitoring%20in%201995.)
12. Buasroung P, Petnak T, Liwtanakitpipat P, Kiertiburanakul S. Prevalence of Diabetes Mellitus in Patients with Tuberculosis: A Prospective Cohort Study. *Int J Infect Dis [Internet].* 2022;116:374–9. Available from: <https://www.sciencedirect.com/science/article/pii/S1201971222000558>
13. Yoo JE, Kim D, Han K, Rhee SY, Shin DW, Lee H. Diabetes Status and Association With Risk of Tuberculosis Among Korean Adults. *JAMA Netw Open [Internet].* 2021 Sep 21;4(9):e2126099–e2126099. Available from: <https://doi.org/10.1001/jamanetworkopen.2021.26099>
14. Katalinic-Jankovic V, Furci L, Cirillo D. Microbiology of Mycobacterium tuberculosis and a new diagnostic test for TB. In: *European Respiratory Monograph.* 2022. p. 54–60.
15. Peng Y-F. Pulmonary tuberculosis and diabetes mellitus: Epidemiology, pathogenesis and therapeutic management (Review). *Med Int [Internet].* 2024;4(1):4. Available from: <https://doi.org/10.3892/mi.2023.128>
16. Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. *J Bras Pneumol publicacao Of da Soc Bras Pneumol e Tisiologia.* 2018 Apr;44(2):145–52.
17. WHO. Global Tuberculosis Report 2022. World Heal Organ [Internet].

2022;1–2. Available from: https://cdn.who.int/media/docs/default-source/hq-tuberculosis/global-tuberculosis-report-2022/global-tb-report-2022-factsheet.pdf?sfvrsn=88f8d76_8&download=true

18. Wu Q, Liu Y, Ma Y-B, Liu K, Chen S-H. Incidence and prevalence of pulmonary tuberculosis among patients with type 2 diabetes mellitus: a systematic review and meta-analysis. *Ann Med* [Internet]. 2022 Dec 31;54(1):1657–66. Available from: <https://doi.org/10.1080/07853890.2022.2085318>
19. Bisht MK, Dahiya P, Ghosh S, Mukhopadhyay S. The cause-effect relation of tuberculosis on incidence of diabetes mellitus. *Front Cell Infect Microbiol*. 2023;13:1134036.
20. Nair A, Greeny A, Nandan A, Sah RK, Jose A, Dyawanapelly S, et al. Advanced drug delivery and therapeutic strategies for tuberculosis treatment. *J Nanobiotechnology* [Internet]. 2023;21(1):1–32. Available from: <https://doi.org/10.1186/s12951-023-02156-y>
21. Maison DP. Tuberculosis pathophysiology and anti-VEGF intervention. *J Clin Tuberc Other Mycobact Dis* [Internet]. 2022;27:100300. Available from: <https://www.sciencedirect.com/science/article/pii/S2405579422000055>
22. Wang M, Liu Y, Liang Y, Naruse K, Takahashi K. Systematic Understanding of Pathophysiological Mechanisms of Oxidative Stress-Related Conditions—Diabetes Mellitus, Cardiovascular Diseases, and Ischemia–Reperfusion Injury. *Front Cardiovasc Med* [Internet]. 2021;8. Available from: <https://www.frontiersin.org/journals/cardiovascular-medicine/articles/10.3389/fcvm.2021.649785>
23. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 Diabetes Mellitus and Altered Immune System Leading to Susceptibility to Pathogens, Especially Mycobacterium tuberculosis. Vol. 8, *Journal of Clinical Medicine*. 2019.
24. Ferlita S, Yegiazaryan A, Noori N, Lal G, Nguyen T, To K, et al. Type 2 diabetes mellitus and altered immune system . *J Clin Med*. 2019;9(12).

25. Santos A, Magro DO, Evangelista-Poderoso R, Saad MJA. Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications. *Diabetol Metab Syndr* [Internet]. 2021;13(1):23. Available from: <https://doi.org/10.1186/s13098-021-00639-2>
26. Oswal N, Lizardo K, Dhanyalayam D, Ayyappan JP, Thangavel H, Heysell SK, et al. Host Metabolic Changes during Mycobacterium Tuberculosis Infection Cause Insulin Resistance in Adult Mice. *J Clin Med*. 2022 Mar;11(6).
27. Liang CP, Han S, Senokuchi T, Tall AR. The macrophage at the crossroads of insulin resistance and atherosclerosis. *Circ Res*. 2017;100(11):1546–55.
28. Kumar NP, Babu S. Impact of diabetes mellitus on immunity to latent tuberculosis infection. *Front Clin Diabetes Healthc* [Internet]. 2023;4. Available from: <https://www.frontiersin.org/journals/clinical-diabetes-and-healthcare/articles/10.3389/fcdhc.2023.1095467>
29. Ngo MD, Bartlett S, Ronacher K. Diabetes-associated susceptibility to tuberculosis: Contribution of hyperglycemia vs. dyslipidemia. *Microorganisms*. 2021;9(11):1–15.
30. Lee P-H, Fu H, Lee M-R, Magee M, Lin H-H. Tuberculosis and diabetes in low and moderate tuberculosis incidence countries. *Int J Tuberc Lung Dis Off J Int Union against Tuberc Lung Dis*. 2018 Jan;22(1):7–16.
31. Balakrishnan S, Vijayan S, Nair S, Subramoniapillai J, Mrithyunjayan S, Wilson N, et al. High Diabetes Prevalence among Tuberculosis Cases in Kerala, India. *PLoS One* [Internet]. 2022 Oct 15;7(10):e46502. Available from: <https://doi.org/10.1371/journal.pone.0046502>
32. Makuka GJ, Balandya E, Munseri P. Burden of active pulmonary tuberculosis among patients with diabetes in Dar es Salaam, Tanzania: a cross-sectional study. *BMJ Open*. 2022 Nov;12(11):e065969.
33. Kementerian Kesehatan RI. Pedoman Nasional Pelayanan Kedokteran :

Tatalaksana Tuberkulosis. Kementrian Kesehat R. 2020;1(2):1–156.

34. Avuthu S, Mahishale V, Patil B, Eti A. Glycemic control and radiographic manifestations of pulmonary tuberculosis in patients with type 2 diabetes mellitus. *Sub-Saharan African J Med* [Internet]. 2015 Jan 1;2(1):5–9. Available from: <https://www.ssajm.org/article.asp?issn=2384-5147>
35. Mahishale V, Avuthu S, Patil B, Lolly M, Eti A, Khan S. Effect of Poor Glycemic Control in Newly Diagnosed Patients with Smear-Positive Pulmonary Tuberculosis and Type-2 Diabetes Mellitus. *Iran J Med Sci*. 2017 Mar;42(2):144–51.
36. Chiang CY, Bai KJ, Lin HH, Chien ST, Lee JJ, Enarson DA, et al. The Influence of Diabetes, Glycemic Control, and Diabetes-Related Comorbidities on Pulmonary Tuberculosis. *PLoS One* [Internet]. 2015 Mar 30;10(3):e0121698. Available from: <https://doi.org/10.1371/journal.pone.0121698>
37. Shebani A, Hnish M, Elmelliti H, Lutf Abdussalam A. Massive Hemoptysis in Pulmonary Tuberculosis From Rasmussen Pseudoaneurysm. *Cureus*. 2022 Oct;14(10):e30117.
38. Chang J-T, Dou H-Y, Yen C-L, Wu Y-H, Huang R-M, Lin H-J, et al. Effect of Type 2 Diabetes Mellitus on the Clinical Severity and Treatment Outcome in Patients With Pulmonary Tuberculosis: A Potential Role in the Emergence of Multidrug-resistance. *J Formos Med Assoc* [Internet]. 2011;110(6):372–81. Available from: <https://www.sciencedirect.com/science/article/pii/S0929664611600557>
39. Gil-Santana L, Almeida JL, Oliveira CAM, Hickson LS, Daltro C, Castro S, et al. Diabetes is associated with worse clinical presentation in tuberculosis patients from Brazil: A retrospective cohort study. *PLoS One*. 2016;11(1).
40. Alisjahbana B, Sahiratmadja E, Nelwan EJ, Purwa AM, Ahmad Y, Ottenhoff THM, et al. The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clin Infect Dis an Off Publ Infect Dis Soc Am*. 2007 Aug;45(4):428–35.

41. Zhang L, Jiang F, Xie Y, Mo Y, Zhang X, Liu C. Diabetic endothelial microangiopathy and pulmonary dysfunction. *Front Endocrinol (Lausanne)*. 2023;14:1073878.
42. Sulistiana R. Correlation between Chest X-Rays and TCM (Rapid Molecular Tests) in Pulmonary Tuberculosis Patients at Anutapura Hospital Palu under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC4.0). *J eduhealth [Internet]*. 2023;14(02):2023. Available from: <http://ejournal.seaninstitute.or.id/index.php/health>
43. Raguraman R, Srivastava A, Munshi A, Ramesh R. Therapeutic approaches targeting molecular signaling pathways common to diabetes, lung diseases and cancer. *Adv Drug Deliv Rev [Internet]*. 2021;178:113918. Available from: <https://www.sciencedirect.com/science/article/pii/S0169409X21003112>
44. Kolahian S, Leiss V, Nürnberg B. Diabetic lung disease: fact or fiction? *Rev Endocr Metab Disord [Internet]*. 2019;20(3):303–19. Available from: <http://dx.doi.org/10.1007/s11154-019-09516-w>
45. Visca D, Pignatti P, Spanevello A, Lucini E, La Rocca E. Relationship between diabetes and respiratory diseases—Clinical and therapeutic aspects. *Pharmacol Res [Internet]*. 2018;137:230–5. Available from: <https://www.sciencedirect.com/science/article/pii/S1043661818309459>
46. van der Zalm MM, Jongen VW, Swanepoel R, Zimri K, Allwood B, Palmer M, et al. Impaired lung function in adolescents with pulmonary tuberculosis during treatment and following treatment completion. *eClinicalMedicine [Internet]*. 2024;67:102406. Available from: <https://doi.org/10.1016/j.eclinm.2023.102406>
47. Wikurendra EA, Herdiani N, Tarigan YG, Kurnianto AA. Risk Factors of Pulmonary Tuberculosis and Countermeasures: A Literature Review. *Open Access Maced J Med Sci [Internet]*. 2021 Nov 9;9(F SE-Narrative Review Article):549–55. Available from: <https://oamjms.eu/index.php/mjms/article/view/7287>

48. Goyal A, Gupta Y, Singla R, Kalra S, Tandon N. American Diabetes Association “Standards of Medical Care-2020 for Gestational Diabetes Mellitus”: A Critical Appraisal. *Diabetes Ther Res Treat Educ diabetes Relat Disord*. 2020 Aug;11(8):1639–44.
49. Sarkar K, Kashyap B, Lnu S, Avasthi RK, Khanna A. Utility of a Clinical Scoring System (Bandim TB Score and Karnofsky Performance Score) to Assess Mycobacterial Burden in Terms of Cartridge-Based Nucleic Acid Amplification Test (CBNAAT) Cycle Threshold Values Among Pulmonary TB Patients. *Cureus*. 2023 Dec;15(12):e50976.
50. Park B, Park J, Shin KM, Lim J-K, Hong J, Cha JG, et al. Ultrasound-guided lung biopsy for small (≤ 2 cm) subpleural lung lesions: comparison of diagnostic yield and safety with larger lesions. *J Thorac Dis*. 2023;15(5):2485–96.